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Abstract: Background: Patients with chronic hepatitis C virus
(HCV) infection who have not had a response to therapy with pegin-
terferon and ribavirin may beneﬁt from the addition of multiple
direct-acting antiviral agents to their treatment regimen.
Methods: This open-label, phase 2a study included an exploratory
cohort of 21 patients with chronic HCV genotype 1 infection who
had not had a response to previous therapy (i.e., had not had P2
log(10) decline in HCV RNA after P12 weeks of treatment with
peginterferon and ribavirin). We randomly assigned patients to
receive the NS5A replication complex inhibitor daclatasvir (60 mg
once daily) and the NS3 protease inhibitor asunaprevir (600 mg
twice daily) alone (group A, 11 patients) or in combination with
peginterferon alfa-2a and ribavirin (group B, 10 patients) for
24 weeks. The primary end point was the percentage of patients with
a sustained virologic response 12 weeks after the end of the treat-
ment period.
Results: A total of 4 patients in group A (36%; 2 of 9 with HCV geno-
type 1a and 2 of 2 with genotype 1b) had a sustained virologic
response at 12 weeks after treatment and also at 24 weeks after
treatment. Six patients (all with HCV genotype 1a) had viral break-
through while receiving therapy, and resistance mutations to both
antiviral agents were found in all cases; 1 patient had a viral
response at the end of treatment but had a relapse after the treat-
ment period. All 10 patients in group B had a sustained virologic
response at 12 weeks after treatment, and 9 had a sustained virologic
response at 24 weeks after treatment. Diarrhea was the mostJournal of Hepatology 20
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SVR, sustained virologic response; DAAs, direct-acting antivirals.common adverse event in both groups. Six patients had transient ele-
vations of alanine aminotransferase levels to more than three times
the upper limit of the normal range.
Conclusions: This preliminary study involving patients with HCV
genotype 1 infection who had not had a response to prior therapy
showed that a sustained virologic response can be achieved with
two direct-acting antiviral agents only. In addition, a high rate of
sustained virologic response was achieved when the two direct-act-
ing antiviral agents were combined with peginterferon alfa-2a and
ribavirin. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov num-
ber, NCT01012895.).
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Approximately 170 million people are infected with hepatitis
C virus (HCV) worldwide. Treatment of genotype 1 naïve chronic
hepatitis C with peginterferon alfa (PegIFN) and ribavirin (RBV)
for 48 weeks results in sustained virologic response (SVR) in
approximately 40% of patients. Retreatment of previous non-
responders to PegIFN/RBV therapy with triple therapy, a protease
inhibitor (telaprevir or boceprevir), PegIFN/RBV, results in an SVR
in less than 30% of cases [1,2]. Direct-acting antivirals (DAAs)
with different viral targets, including NS3 protease inhibitors,
nucleoside/nucleotide analogues and non-nucleoside inhibitors
of the RNA-dependent RNA polymerase, and NS5A inhibitors
are under development [3]. Gane and colleagues found that a
combination of two DDAs can suppress HCV RNA in genotype 1
non-responder patients but the treatment with the DAAs combi-
nation was limited to 13 days and was followed immediately by
treatment with PegIFN/RBV, thus preventing the assessment of
SVR with DAAs alone [4]. Studies of DAAs combinations in the
genotype 1 non-responder population are warranted.
Recently, Lok et al., in a preliminary study including patients
with HCV genotype 1 infection who were non-responders to prior
therapy, showed that an SVR could be achieved with two DAAs
[5].
Daclatasvir (BMS-790052) is a ﬁrst-in-class, highly selective
HCV NS5A replication complex inhibitor with picomolar potency
in vitro [6]. NS5A is a membrane-associated phosphoprotein pres-
ent in basally phosphorylated (p56) and hyperphosphorylated
(p58) forms. It was previously reported that only p58-defective
mutants could be complemented in trans, and NS5A is involved
in HCV virion production, suggesting that different forms of
NS5A exert multiple functions at various stages of the viral life12 vol. 57 j 455–457
Group A: Daclastavir + Asunaprevir
Group B: Daclastavir + Asunaprevir + PegIFNα/RBV
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Fig. 1. Virologic response. (Group A) Four patients (36%) had an SVR at 12 weeks
after the end of the treatment period, and all four also had an SVR at week 24 after
treatment. Six patients (all with HCV genotype 1a) had a viral breakthrough while
receiving therapy; 1 patient had a viral response at the end of treatment but
relapsed after the treatment period. (Group B) (1) 10/10 patients had undetect-
able HCV RNA by week 6 of therapy with no viral breakthrough; (2) 10/10
patients achieved SVR12 and 9/10 achieved SVR24; (3) 1 patient <LLOQ at week 24
post-treatment was undetectable on retesting, 1 and 3 months later. Adapted
from [5], with permission from the Massachusetts Medical Society.
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cycle. The N terminus of NS5A (domain I) has been crystallized in
alternative dimeric forms and contains both zinc- and RNA-bind-
ing domains, properties that have been demonstrated in vitro.
Daclatasvir is active at picomolar concentrations in vitro towards
replicons expressing a broad range of HCV genotypes and acts in
an additive to synergistic way with interferon and other small
molecule antiviral compounds [6,7]. The resistance proﬁle of
BMS-790052 reveals that inhibitor sensitivity maps to the N ter-
minus of domain 1 of NS5A [6–8]. In addition, it has been demon-
strated that NS5A inhibitors could block hyperphosphorylation of
NS5A, which is believed to play an essential role in the viral life
cycle.
Asunaprevir (BMS-650032) is a highly active HCV NS3 prote-
ase inhibitor. NS3 serine protease is located at the N-terminal
region of NS3. The NS3 serine protease domain associates with
the NS4A co-factor to cleave four speciﬁc sites. This enzyme
has been extensively characterized at the biochemical level and
its structure is known [9]. The serine protease activity of NS3 is
an attractive target for new drugs that could effectively block
viral replication. Protease inhibitors have high anti-viral efﬁcacy
and usually a low genetic barrier. The genetic barrier to resis-
tance is deﬁned as the number of amino acid substitutions
required to confer full resistance to a drug. The genetic barrier
to protease inhibitors and NS5A inhibitors is usually low.
Both daclatasvir and asunaprevir produce marked declines in
HCV RNA levels in patients with HCV genotype 1 infection [10,11]
and administration of the two drugs in combination did not pro-
duce a clinically meaningful pharmacokinetic interaction [12].
In the study reported by Lok et al., patients with HCV genotype
1 infection, with no response to previous treatment with PegIFN/
RBV, were randomly assigned to receive daclatasvir (60 mg once
daily) and asunaprevir (600 mg twice daily) alone (group A, 11
patients) or in combination with PegIFNa-2a and RBV (group B,
10 patients) for 24 weeks [5]. A total of 4 patients in group A
(36%; 2 of 9 with HCV genotype 1a and 2 of 2 with genotype
1b) had an SVR 12 weeks after treatment and also 24 weeks after
treatment (Fig. 1). Six patients (all with HCV genotype 1a) had a
viral breakthrough while receiving therapy, and resistance muta-
tions to both antiviral agents were found in all cases; 1 patient
had a viral response at the end of treatment but relapsed after
the treatment period.
Viral variants in the NS5A domain included Q30R, L31M/V,
and Y93C/N; variants in the NS3 protease domain included
R155K and D168A/E/T/V/Y. The patient with a viral relapse had
a pre-existing NS3 protease resistance variant, R155K, at baseline
and at the time of viral relapse, whereas the NS5A resistance var-
iant Q30E was only detected at relapse. Although there were only
2 patients with HCV genotype 1b infection in group A, the obser-
vation that both of the patients had an SVR with two direct-act-
ing antiviral agents alone may reﬂect a higher resistance barrier
for this combination of drugs in patients with HCV genotype 1b
infection than in those with HCV genotype 1a infection. The high
frequency of resistance seen in patients with HCV genotype 1a
infection who were treated with DAAs alone suggests that studies
of DAAs combinations without PegIFN/RBV in patients with HCV
genotype 1a infection should proceed carefully. In group B, the
inclusion of Peg IFN/RBV with daclatasvir and asunaprevir pro-
vided sufﬁcient antiviral activity to suppress the emergence of
resistance. All 10 patients in group B had an SVR 12 weeks after
treatment, and 9 had an SVR 24 weeks after treatment.456 Journal of Hepatology 201It should be noticed that among the 14 patients who had an
SVR 12 weeks after treatment, a HCV RNA level of less than
25 IU/ml was detected in 1 patient 24 weeks after treatment
and in 2 other patients 48 weeks after treatment. All 3 patients
had undetectable HCV RNA on re-testing. These data indicate that
late relapse is unlikely to occur in patients who have an SVR with2 vol. 57 j 455–457
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the DAAs combination, 12 weeks after treatment as previously
established with PegIFN/RBV treatment [13].
The most common adverse events were diarrhea, fatigue,
headache, and nausea. Most adverse events were mild to moder-
ate. There were no deaths, serious adverse events, or discontinu-
ations of study treatment due to adverse events. Diarrhea was the
most common adverse event in both groups. Six patients had
transient elevation of alanine aminotransferase levels to more
than three times the upper limit of the normal range.
Finally, Lok et al. reported interesting results with daclatasvir
and asunaprevir combination in HCV genotype 1 non-responders
to previous treatment with PegIFN plus ribavirin [5]. Similarly,
Chayama et al. reported impressive results in a pilot study of
combination therapy with asunaprevir and daclatasvir in 10 Jap-
anese patients with HCV genotype 1b infection and who had not
responded to previous therapy with PegIFN/RBV: nine patients
achieved an SVR [14]. Several studies of DAA combinations are
ongoing with different HCV targets: [3,5,14,15]. Preliminary
results of DAA combinations show increased antiviral efﬁcacy,
reduced resistance and a good safety proﬁle. It is important to
note that some of these drugs have pan-genotypic activity. This
rapid progress strongly suggests that in the near future, IFN-free
short duration DAA combinations will make HCV the ﬁrst chronic
viral infection to be eradicated worldwide.Conﬂict of interest
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